Mark Cragg

Mark Cragg is Professor of Experimental Cancer Biology in the School of Cancer Sciences at the University of Southampton Faculty of Medicine. His research concerns how therapeutics result in tumour regression with a focus on antibodies and small molecules, with a particular interest in Fc receptors and TNFR family members. The aim is to understand how these therapeutics delete tumour cells, how resistance occurs, and how it might be overcome through antibody engineering. In his most recent work, Professor Cragg has studied antibodies directed to immunostimulatory receptors as an untapped source for immunotherapy, combining structural biology, molecular dynamics simulations, and protein engineering to elicit immune stimulation. Throughout the strategy undertaken is highly translational with iterative cycling between in vitro experiments, appropriate in vivo model systems, and primary clinical material.